<DOC>
	<DOCNO>NCT02626221</DOCNO>
	<brief_summary>This non-interventional , multi-country , Latin American study utilize prospective single-cohort design . Eligible CU patient enrol study follow 24 month ( Â± 6 week ) . In accordance observational nature study , intervention interference routine care patient base solely clinical judgment treat physician . However , respect frequency schedule assessment , schedule include Table 7-1 recommend . The selection treatment CU clearly separate decision include patient study , make discretion treat physician accordance standard medical practice , investigator 's clinical judgment , global urticarial guideline . In order prevent selection bias , investigator offer enrollment consecutive patient meet study criterion , likely available full duration follow-up period 24 month , willing participate study . The overall objective study evaluate real-life CU disease burden , current treatment pattern use health care resource patient refractory H1-antihistamine treatment</brief_summary>
	<brief_title>A Worldwide Antihistamine-Refractory Chronic Urticaria Patient Evaluation Latin America Canada ( AWARE-LACan )</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Histamine Antagonists</mesh_term>
	<mesh_term>Histamine H1 Antagonists</mesh_term>
	<criteria>Men Women least 18 year age old . Patient medically confirm diagnosis chronic urticaria present 2 month . Patient treat least one course H1 antihistamines refractory treatment Patient provide write informed consent allow use anonymous data purpose study Patient currently participate clinical trial . Patient , opinion treat physician , unlikely available full duration followup period 24 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>